natgillin/translations-raw huggingface dataset:
All patients should have liver function tests to determine whether they have hepatic impairment before starting and during pazopanib therapy (see section 4.4). 
Pri vseh bolnikih je treba opraviti teste jetrne funkcije, da bi ugotovili morebitno okvaro jeter; opraviti jih je treba pred začetkom zdravljenja in med zdravljenjem s pazopanibom (glejte poglavje 4.4).
Continue on pazopanib with weekly monitoring of liver function until transaminases return to Grade 1 or baseline. 
Nadaljujte zdravljenje s pazopanibom s tedenskim spremljanjem delovanja jeter, dokler se vrednosti aminotransferaz ne vrnejo na stopnjo 1 ali izhodiščno vrednost.
The primary objective of this study was to evaluate and compare PFS in patients treated with pazopanib to those treated with sunitinib. 
Primarni cilj študije je bila ocena in primerjava preživetja brez napredovanja pri bolnikih, zdravljenih s pazopanibom, in bolnikih, zdravljenih s sunitinibom.
Votrient can cause separation or tear of the lining of the back part of the eye (retinal detachment or tear). 
Zdravilo Votrient lahko povzroči odstop ali pretrganje tanke plasti na zadnji strani očesnega zrkla (odstop mrežnice ali pretrganje mrežnice).
Votrient is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. 
Zdravilo Votrient je pri odraslih indicirano kot zdravilo prvega izbora za zdravljenje napredovalega karcinoma ledvičnih celic (RCC - renal cell carcinoma) in pri bolnikih, ki so zaradi napredovale bolezni predhodno prejemali zdravljenje s citokini.
If pazopanib is used during pregnancy, or if the patient becomes pregnant while receiving pazopanib, the potential hazard to the foetus should be explained to the patient. 
Če se pazopanib uporablja med nosečnostjo, ali če bolnica med zdravljenjem s pazopanibom zanosi, ji je treba pojasniti možno tveganje za plod.
The efficacy and safety of pazopanib in STS were evaluated in a pivotal Phase III randomised, double-blind, placebo-controlled multicentre study (VEG110727). 
Varnost in učinkovitost pazopaniba pri STS so ocenili v ključni randomizirani, dvojno slepi, s placebom kontrolirani multicentrični študiji faze III (VEG110727).
Infections (with or without neutropenia)† 
Infekcijske in parazitske bolezni pogosti okužbe (z nevtropenijo ali brez nje)†
Women of childbearing potential should be advised to use adequate contraception during treatment and for at least 2 weeks after the last dose of pazopanib and to avoid becoming pregnant while receiving treatment with pazopanib. 
Ženskam v rodni dobi je treba svetovati uporabo primerne metode kontracepcije med zdravljenjem in še najmanj 2 tedna po zadnjem odmerku pazopaniba in pojasniti, da med zdravljenjem s pazopanibom ne smejo zanositi.
Fatal perforation events have occurred. 
Pojavile so se perforacije s smrtnim izidom.
Not known (frequency cannot be estimated from the available data): - an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall 
Neznana pogostnost (je ni mogoče ocenti iz razpoložljivih podatkov): - razširitev in oslabitev stene krvne žile ali raztrganina v steni krvne žile (anevrizme in disekcije arterij).
Furthermore, inhibition of BCRP and P-gp by pazopanib in the gastrointestinal tract cannot be excluded. 
Poleg tega ni mogoče izključiti zavrtja BCRP in P-gp s pazopanibom v prebavilih.
A synthetic intermediate in manufacture of pazopanib, which is also present in the final drug substance in low amounts, was not mutagenic in the Ames assay but genotoxic in the mouse lymphoma assay and in vivo mouse micronucleus assay. 
Sintetični intermediat, ki se uporablja pri izdelavi pazopaniba in je v majhnih količinah prisoten tudi v končni zdravilni učinkovini pri Amesovem testu ni deloval mutageno, je pa bil genotoksičen pri testu na mišjem limfomu ter in vivo testu na mišjih mikronukleusih.
Concomitant administration of pazopanib with uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) substrates (e.g. irinotecan) should be undertaken with caution since pazopanib is an inhibitor of UGT1A1 (see section 4.5). 
Pri sočasni uporabi pazopaniba in substratov za uridin-difosfat-glukuronoziltransferazo 1A1 (UGT1A1) (npr. irinotekan) je potrebna previdnost, ker je pazopanib inhibitor UGT1A1 (glejte poglavje 4.5).
Dose modification (decrease or increase) should be in 200 mg decrements or increments in a stepwise fashion based on individual tolerability in order to manage adverse reactions. 
Odmerek je treba prilagajati (zniževati ali zviševati) postopoma, z nižanjem ali višanjem odmerka v korakih po 200 mg in pri tem upoštevati prenašanje zdravila pri posameznem bolniku zaradi obvladovanja neželenih učinkov.
Effect of food on pazopanib 
Vpliv hrane na pazopanib
In each treatment group, there was a slightly greater percentage of subjects in the 2+ lines of prior systemic therapy for advanced disease (58% and 55%, respectively, for placebo and pazopanib treatment arms) compared with 0 or 1 lines of prior systemic therapy (42% and 45%, respectively, for placebo and pazopanib treatment arms). 
V vsaki terapevtski skupini je bil rahlo večji odstotek preiskovancev z 2 ali več linijami predhodnega sistemskega zdravljenja napredovale bolezni (58 % v skupini s placebom, 55 % v skupini s pazopanibom) kot z 0 ali 1 linijo predhodnega sistemskega zdravljenja (42 % v skupini s placebom in 45 % v skupini s pazopanibom).
No statistical differences were observed between treatment groups for Global Quality of Life using EORTC QLQ-C30 and EuroQoL EQ-5D. 
Skupna kvaliteta življenja na osnovi EORTC QLQ-C30 in EuroQoL EQ-5D se med obema skupinama zdravljenja statistično ni razlikovala.
It can occur in muscles, blood vessels, fat tissue or other tissues that support, 
Pojavi se lahko v mišicah, žilah, maščobnem tkivu ali drugih tkivih, ki podpirajo, obdajajo in varujejo organe.
Patients developing PRES/RPLS should permanently discontinue treatment with pazopanib. 
Bolniki, ki se jim pojavi PRES/RPLS, morajo trajno prenehati z zdravljenjem s pazopanibom.
Co-administration of pazopanib with other strong inhibitors of the CYP3A4 family (e.g. itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase pazopanib concentrations. 
Pri sočasni uporabi pazopaniba in ostalih zdravil iz skupine močnih zaviralcev CYP3A4 (npr. itrakonazol, klaritromicin, atazanavir, indinavir, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, vorikonazol) se koncentracije pazopaniba lahko povečajo.
Votrient can cause a tear (perforation) in your stomach or intestinal wall or the development of an abnormal connection between two parts of your digestive tract (a fistula). 
Zdravilo Votrient lahko povzroči predrtje (perforacijo) stene želodca ali črevesa ali razvoj neobičajnih povezav med dvema deloma prebavnega trakta (fistula).
Concomitant treatment with strong inhibitors of CYP3A4, P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) should be avoided due to risk of increased exposure to pazopanib (see section 4.5). 
Sočasnemu zdravljenju z močnimi zaviralci CYP3A4, P-glikoproteina (P-gp) ali proteina BCRP se je treba izogniti, ker obstaja tveganje večje izpostavljenosti pazopanibu (glejte poglavje 4.5).
Pazopanib should be administered at least 1 hour before or 2 hours after administration of short-acting antacids. 
Pazopanib je treba vzeti vsaj 1 uro pred ali 2 uri po uporabi kratkodelujočih antacidov.
Table 6 Overall efficacy results in STS by independent assessment (VEG110727) 
Preglednica 6 Rezultati celokupne učinkovitosti pri STS po neodvisni oceni (VEG110727)
- If you do become pregnant during treatment with Votrient, tell your doctor. 
- Če med zdravljenjem z zdravilom Votrient zanosite, o tem obvestite svojega zdravnika.
In a randomised study comparing pazopanib and sunitinib in RCC (VEG108844), subjects had baseline and follow up LVEF measurements. 
V randomizirani primerjalni študiji pazopaniba in sunitiniba pri karcinomu ledvičnih celic (VEG108844) so preiskovancem opravili izhodiščno meritev in kontrolne meritve LVEF.
The safety and efficacy of pazopanib in RCC were evaluated in a randomised, double-blind, placebo-controlled multicentre study. 
Varnost in učinkovitost pazopaniba pri karcinomu ledvičnih celic je bila ovrednotena z randomizirano, dvojno slepo, s placebom nadzorovano multicentrično študijo.
It is not known whether pazopanib or its metabolites are excreted in human milk. 
Ni znano, ali se pazopanib ali njegovi presnovki izločajo z materinim mlekom.
Signs and symptoms of stroke may include: - numbness or weakness on one side of your body - difficulty talking - headache - dizziness 
Znaki in simptomi možganske kapi lahko vključujejo: - odrevenelost ali šibkost ene strani vašega telesa, - težave pri govorjenju, - glavobol, - omotico.
Interruption of pazopanib and/or dose reduction should be combined with treatment of hypertension (if present, refer to hypertension warning section above) in patients with significant reductions in LVEF, as clinically indicated. 
Pri bolnikih s pomembnim zmanjšanjem LVEF je treba zdravljenje s pazopanibom prekiniti in/ali zmanjšati odmerek ter to kombinirati z zdravljenjem hipertenzije (če je ta prisotna, glejte poglavje z opozorili glede hipertenzije zgoraj), kot je klinično indicirano.
Venous thromboembolic events 
Venski trombembolični dogodki
In the cytokine pre-treated subgroup, the majority (75%) had received interferon-based treatment. 
V podskupini bolnikov, ki so se predhodno že zdravili s citokini, se je večina bolnikov (75 %) zdravila z interferoni.
Pre-clinical studies in animals have shown reproductive toxicity (see section 5.3). 
Predklinične študije na živalih so pokazale reproduktivno toksičnost (glejte poglavje 5.3).
Endpoints / study population 
Opazovani dogodek/Študijska populacija
Within each system organ class, adverse reactions with the same frequency are presented in order of decreasing seriousness. 
V razvrstitvah pogostnosti znotraj posameznega organskega sistema so neželeni učinki navedeni po padajoči resnosti.
In juvenile toxicity studies, when pre-weaning rats were dosed from day 9 post partum through to day 14 post partum, pazopanib caused mortalities and abnormal organ growth/maturation in kidney, lung, liver and heart, at a dose approximately 0.1 times the clinical exposure based on AUC in adult humans. 
V študijah juvenilne toksičnosti, v katerih so podgane pred prenehanjem dojenja prejemale pazopanib od 9. do 14. postpartalnega dneva, je pazopanib povzročil poginjanje in nenormalno rast/dozorevanje organov (ledvic, pljuč, jeter in srca) v odmerkih, ki so bili približno 0,1-kratnik klinične izpostavljenosti na podlagi AUC pri odraslih ljudeh.
A similar improvement in PFS based on investigator assessments was observed in the pazopanib arm compared with the placebo arm (in the overall ITT population HR: 0.39; 95% CI, 0.30 to 0.52, p <0.001). 
Izboljšanje PFS v skupini s pazopanibom v primerjavi s placebom je bilo po oceni raziskovalcev podobno (razmerje ogroženosti v celotni populaciji ITT: 0,39, 95 % IZ od 0,30 do 0,52, p < 0,001).
Care should be taken when pazopanib is co-administered with other oral BCRP and P-gp substrates. 
Previdnost je potrebna, če je pazopanib uporabljen hkrati z drugimi peroralnimi substrati BCRP in P-gp.
In a rat male fertility study, there was no effect on mating or fertility, but decreased testicular and epididymal weights were noted with reductions in sperm production rates, sperm motility, and epididymal and testicular sperm concentrations observed at exposures 0.3 times human exposure based on AUC. 
Pri študiji plodnosti pri samcih podgan niso opazili učinkov na parjenje ali plodnost, opazili pa so zmanjšanje mase mod in epididimisov z manjšim nastajanjem sperme, manjšo gibljivostjo semenčic in manjšo koncentracijo sperme v nadmodkih in modih, in sicer pri izpostavljenosti, ki je na osnovi AUC ustrezala 0,3-kratni izpostavljenosti človeka.
Proliferative hepatic lesions (eosinophilic foci and adenoma) were seen in female mice at exposures 2.5 times human exposure based on AUC. 
Proliferativne jetrne spremembe (eozinofilna žarišča in adenomi) so bili pri mišjih samicah opaženi pri izpostavljenosti, ki je bila na osnovi AUC 2,5-krat večja od izpostavljenosti človeka.
Thirteen of the 15 subjects in the pazopanib arm of the STS Phase III study had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk by increasing cardiac after-load. 
V študiji III. faze pri STS je imelo v kraku s pazopanibom sočasno hipertenzijo 13 od 15 preiskovancev; hipertenzija je morda poslabšala moteno delovanje srca pri ogroženih bolnikih s povečanjem sistoličnega bremena ("afterload").
Votrient can cause problems with your liver which may develop into serious conditions such as liver dysfunction and liver failure, which may be fatal. 
Zdravilo Votrient lahko povzroči težave z jetri, ki se lahko poslabšajo do resnega stanja, kot sta slabše delovanje jeter ali odpoved jeter, ki je lahko smrtna.
HR (95% CI) 
ROg (95 % IZ)
Tell your doctor if you notice any unusual changes in your heart beat, such as beating too fast or too slow. 
Če zaznate kakršne koli neobičajne spremembe srčnega utripa, kot je prepočasno ali prehitro utripanje srca, o tem obvestite svojega zdravnika.
Your treatment will be restarted when the wound has adequately healed. 
Zdravljenje z zdravilom Votrient se lahko ponovno uvede, ko bo rana ustrezno zaceljena.
Cases of hyperglycaemia have been observed during concomitant treatment with ketoconazole. 
Med sočasnim zdravljenjem s ketokonazolom so bili opisani primeri hiperglikemije.
Patients over 60 years of age may be at greater risk for mild (>3 x ULN) to severe (>8 x ULN) elevation of ALT. 
Tveganje za blago (> 3-kratna ZMN) do hudo (> 8-kratna ZMN) zvišanje vrednosti ALT je lahko večje pri bolnikih, starejših od 60 let.
Votrient is not recommended for people aged under 18. 
Pri bolnikih, mlajših od 18 let, uporaba zdravila Votrient ni priporočljiva.
If no medically acceptable alternative to a strong CYP34A inhibitor is available, the dose of pazopanib should be reduced to 400 mg daily during concomitant administration. 
Če ni medicinsko sprejemljive alternative uporabi močnega zaviralca CYP34A, je treba med sočasno uporabo odmerek pazopaniba zmanjšati na 400 mg na dan (glejte poglavje 4.4).
Pazopanib is for oral use. 
Pazopanib je namenjen peroralni uporabi.
The primary objective of the study was progression-free survival (PFS assessed by independent radiological review); the secondary endpoints included overall survival (OS), overall response rate and duration of response. 
Primarni cilj študije je bila ocena in primerjava obeh terapevtskih skupin glede preživetja brez napredovanja (PFS, ki je bilo ocenjeno z neodvisnim radiološkim pregledom); med sekundarnimi opazovanimi dogodki pa so bili celokupno preživetje (OS), delež celokupnega odziva in trajanje odziva.
In such cases there should be close attention to adverse drug reaction, and further dose reduction may be considered if possible drug-related adverse events are observed. 
V takšnih primerih je treba biti pozoren na neželene učinke in če se pojavijo z zdravilom povezani neželeni učinki, pride v poštev dodatno zmanjšanje odmerka.
Concomitant administration of pazopanib with esomeprazole decreases the bioavailability of pazopanib by approximately 40% (AUC and Cmax), and co-administration of pazopanib with medicines that increase gastric pH should be avoided. 
Sočasna uporaba pazopaniba in esomeprazola zmanjša biološko uporabnost pazopaniba za približno 40 % (AUC in Cmax); hkratni uporabi pazopaniba z zdravili, ki zvišajo pH v želodcu, se je treba izogniti.
Normal hepatic function 
Normalno delovanje jeter
Hypothyroidism 83 (7%) 
Bolezni endokrinega sistema pogosti hipotiroidizem 83 (7 %)
Votrient can affect heart rhythm which in some people can develop into a potentially serious heart condition known as torsade de pointes. 
Spremembe srčnega ritma (podaljšanje intervala QT) Zdravilo Votrient lahko vpliva na srčni ritem, kar se pri posameznih bolnikih lahko razvije v potencialno resno hitro utripanje srca, poznano kot torsade de pointes.
The majority of these cases were Palmar-plantar erythrodysaesthesia syndrome d Venous thromboembolic events - includes Deep vein thrombosis, Pulmonary embolism and Thrombosis terms e 
V večini primerov je šlo za sindrom palmarno-plantarne eritrodizestezije d Venski trombembolični dogodki - vključuje izraze globoka venska tromboza, pljučna embolija in tromboza e
Results from a meta-analysis using pooled data from clinical studies with pazopanib show that ALT >3x ULN was reported in 126/895 (14%) of patients who did not use statins, compared with 11/41 (27%) of patients who had concomitant use of simvastatin (p = 0.038). 
Rezultati metanalize, ki je uporabila združene podatke kliničnih raziskav s pazopanibom so pokazali, da so ALT > 3-kratno zgornjo mejo normalnih vrednosti zabeležili pri 126 od 895 bolnikov (14 %), ki niso uporabljali statinov, in pri 11 od 41 bolnikov (27 %) bolnikov, ki so sočasno uporabljali simvastatin (p = 0,038).
Magnesium stearate Microcrystalline cellulose Povidone (K30) Sodium starch glycolate 
Jedro tablete magnezijev stearat mikrokristalna celuloza povidon (K30) natrijev karboksimetilškrob
Adipocytic sarcoma (all subtypes), all rhabdomyosarcoma that were not alveolar or pleomorphic, chondrosarcoma, osteosarcoma, Ewing tumours/primitive neuroectodermal tumours (PNET), GIST, dermofibromatosis sarcoma protuberans, inflammatory myofibroblastic sarcoma, malignant mesothelioma and mixed mesodermal tumours of the uterus. 
Adipocitni sarkom (vsi podtipi), vsi rabdomiosarkomi, ki niso bili alveolarni ali pleomorfni, hondrosarkom, osteosarkom, Ewingovi tumorji/primitivni nevroektodermalni tumorji (PNET), GIST, dermatofibromatosis sarcoma protuberans, vnetni miofibroblastni sarkom, maligni mezoteliom in mešani mezodermalni tumorji maternice.
How to take Votrient 
Kako jemati zdravilo Votrient
Other important serious adverse reactions identified in STS studies included venous thromboembolic events, left ventricular dysfunction and pneumothorax. 
Med drugimi pomembnimi resnimi neželenimi učinki, ugotovljenimi v študijah pri STS, so bili venski trombembolični dogodki, moteno delovanje levega prekata in pnevmotoraks.
Care should be taken when pazopanib is co-administered with substrates of UGT1A1. 
Previdnost je potrebna, če je pazopanib uporabljen hkrati s substrati UGT1A1.
There are no animal data on the excretion of pazopanib in animal milk. 
Podatki o izločanju pazopaniba z mlekom pri živalih niso na voljo.
Fertility may be affected by treatment with Votrient. 
Zdravljenje z zdravilom Votrient lahko vpliva na plodnost.
CYP3A4 inducers such as rifampin may decrease plasma pazopanib concentrations. 
Induktorji CYP3A4, kot je rifampicin, lahko zmanjšajo koncentracije pazopaniba v plazmi.
In the three smallest of these 20 subgroups, the point estimate of the hazard ratio exceeded 1.25; i.e. in subjects with no prior nephrectomy (n=186, HR=1.403, 95% CI (0.955, 2.061)), baseline LDH >1.5 x ULN (n=68, HR=1.72, 95% CI (0.943, 3.139)), and MSKCC: poor risk (n=119, HR=1.472, 95% CI (0.937, 2.313)). 
V treh najmanjših od teh 20 podskupin je točkovna ocena razmerja ogroženosti presegla 1,25; te podskupine so bile preiskovanci brez predhodne nefrektomije (n = 186, Rog = 1,403, 95 % IZ (0,955, 2,061)), izhodiščna LDH > 1,5 x ZMN (n = 68, Rog = 1,72, 95 % IZ (0,943; 3,139)) in MSKCC: neugodno tveganje (n = 119, Rog = 1,472, 95 % IZ (0,937; 2,313)).
Importantly, only patients with selective histological subtypes of STS were allowed to participate to the study, therefore efficacy and safety of pazopanib can only be considered established for those subgroups of STS and treatment with pazopanib should be restricted to such STS subtypes. 
Učinkovitost in varnost pazopaniba sta torej ugotovljeni le za te podskupine STS in zdravljenje s pazopanibom mora biti omejeno na te podvrste STS.
If you forget to take Votrient Do not take a double dose to make up for a forgotten dose. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Grapefruit juice contains an inhibitor of CYP3A4 and may also increase plasma concentrations of pazopanib. 
Sok grenivke vsebuje zaviralec CYP3A4 in tudi lahko poveča koncentracije pazopaniba v plazmi.
Clinical studies of pazopanib in combination with pemetrexed (non-small cell lung cancer [NSCLC]) and lapatinib (cervical cancer) were terminated early due to concerns over increased toxicity and/or mortality, and a safe and effective combination dose has not been established with these regimens. 
Klinične študije pazopaniba v kombinaciji s pemetreksedom (nedrobnocelični pljučni rak (NDCPR)) oziroma lapatinibom (rak materničnega vratu) so se končale predčasno zaradi problemov z večjo toksičnostjo in/ali umrljivostjo.
Male patients (including those who have had vasectomies) should use condoms during sexual intercourse while taking pazopanib and for at least 2 weeks after the last dose of pazopanib to avoid potential exposure to the medicinal product for pregnant partners and female partners of reproductive potential. 
Bolniki moškega spola (tudi tisti, ki so imeli vazektomijo) morajo v času jemanja pazopaniba in še najmanj 2 tedna po zadnjem odmerku pazopaniba pri spolnih odnosih uporabljati kondom, s čimer zmanjšujejo možnost, da bi nosečo partnerko oziroma partnerko v rodni dobi izpostavljali zdravilu.
The European Medicines Agency has waived the obligation to submit the results of studies with Votrient in all subsets of the paediatric population in treatment of kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney) (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Votrient za vse podskupine pediatrične populacije za zdravljenje ledvičnega karcinoma in karcinoma ledvičnega pielona (izključujoč nefroblastom, nefroblastomatozo, svetlocelični sarkom, mezoblastni nefrom, ledvični medularni karcinom in rabdoidni tumor ledvic) (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
The primary objective of the study was to evaluate and compare the two treatment arms for progression-free survival (PFS) and the principle secondary endpoint was overall survival (OS). 
Primarni cilj študije je bil ovrednotiti čas preživetja brez napredovanja bolezni (PFS - progression-free survival) in ga primerjati med obema skupinama zdravljenja, glavni sekundarni opazovani dogodek pa skupno preživetje (OS - overall survival).
Pazopanib is a UGT1A1 inhibitor. 
Pazopanib je zaviralec UGT1A1.
Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and discontinue pazopanib in patients developing ILD or pneumonitis. 
Bolnike nadzorujte glede pljučnih simptomov, ki nakazujejo na IBP/pnevmonitis in pri bolnikih, ki se jim razvije IBP ali pnevmonitis, zdravljenje s pazopanibom zaključite.
Administration of a pazopanib 400 mg crushed tablet increased AUC(0-72) by 46% and Cmax by approximately 2 fold and decreased tmax by approximately 2 hours compared to administration of the whole tablet. 
Pri uporabi zdrobljene 400 mg tablete pazopaniba se je vrednost AUC(0-72) povečala za približno 46 %, Cmax za približno 2-krat, vrednost tmax pa skrajšala za približno 2 uri v primerjavi z uporabo cele tablete.
Laboratory monitoring of thyroid function should be performed periodically and managed as per standard medical practice. 
Periodično je treba opravljati laboratorijske preiskave delovanja ščitnice in po potrebi ukrepati v skladu z ustaljeno medicinsko prakso.